Small airways disease in chronic obstructive pulmonary disease

References

• Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. The Lancet Respir Med. 2022;10(5):447–458. doi: 10.1016/S2213-2600(21)00511-7
   PubMed Web of Science ®Google Scholar
• Li X, Cao X, Guo M, et al. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the global burden of disease study 2017. BMJ. 2020 Feb 19 ;368:m234. doi: 10.1136/bmj.m234 Erratum in: BMJ. 2020 Aug 6;370:m3150. doi: 10.1136/bmj.m3150. PMID: 32075787; PMCID: PMC7190065.
   PubMed Web of Science ®Google Scholar
• Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 Report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi: 10.1183/13993003.00239-2023
   PubMed Web of Science ®Google Scholar
• Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. The N Engl J Med (Print). 1968;278(25):1355–1360. doi: 10.1056/NEJM196806202782501
   PubMed Web of Science ®Google Scholar
• Hogg JC, McDonough JE, Suzuki M. Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest. 2013;143(5):1436–1443. doi: 10.1378/chest.12-1766
   PubMed Web of Science ®Google Scholar
• McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575. doi: 10.1056/NEJMoa1106955
   PubMed Web of Science ®Google Scholar
• Koo H-K, Vasilescu DM, Booth S, et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. The Lancet Respir Med. 2018;6(8):591–602. doi: 10.1016/S2213-2600(18)30196-6
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Pisi R, Aiello M, et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the Impact of disease. Respiration. 2017;93(1):32–41. doi: 10.1159/000452479
   PubMed Web of Science ®Google Scholar
• Ritchie AI, Donaldson GC, Hoffman EA, et al. Structural predictors of lung function decline in young smokers with normal spirometry. Am J Respir Crit Care Med. 2024;209(10):1208–1218. doi: 10.1164/rccm.202307-1203OC
   PubMed Web of Science ®Google Scholar
• Mead J. The lung’s “quiet zone”. N Engl J Med (Print). 1970;282(23):1318–1319. doi: 10.1056/NEJM197006042822311
   PubMedGoogle Scholar
• Hogg JC, Paré PD, Hackett T-L. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol Rev. 2017;97(2):529–552. doi:10.1152/physrev.00025.2015
   PubMed Web of Science ®Google Scholar
• 2024 GOLD report - global initiative for chronic obstructive lung disease - GOLD (goldcopd.Org). 2024.
   Google Scholar
• Verleden SE, Hendriks JMH, Snoeckx A, et al. Small airway disease in pre-chronic obstructive pulmonary disease with emphysema: a cross-sectional study. Am J Respir Crit Care Med. 2024;209(6):683–692. doi: 10.1164/rccm.202301-0132OC
   PubMed Web of Science ®Google Scholar
• Agustí A, Hughes R, Rapsomaki E, et al. The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort. ERJ Open Res. 2024;10(1):00895–2023. doi: 10.1183/23120541.00895-2023
   PubMedGoogle Scholar
• Zhang Y, Zhang H, Su X, et al. Analysis of influencing factors and a predictive model of small airway dysfunction in adults. BMC Pulm Med. 2023;23(1):141. doi: 10.1186/s12890-023-02416-5
   PubMed Web of Science ®Google Scholar
• Lavorini F, Pedersen S, Usmani OS. Confusion, and misconceptions related to small airways directed therapy. Chest. 2017;151(6):1345–1355. doi: 10.1016/j.chest.2016.07.035
   PubMed Web of Science ®Google Scholar
• Weibel ER. Morphometry of the human lung. New York (NY): Acedemic Press Inc; 1963.
   Google Scholar
• Hyde DM, Hamid Q, Irvin CG. Anatomy, pathology, and physiology of the tracheobronchial tree: emphasis on the distal airways. J Allergy Clin Immunol. 2009;124(6 Suppl):S72–S77. doi: 10.1016/j.jaci.2009.08.048
   PubMed Web of Science ®Google Scholar
• Baker DJ. The structure of the airways and lungs. In: Artificial ventilation: a basic ClinicalGuide. Springer International Publishing; 2020. p. 27–42.
   Google Scholar
• Virchow JC. Asthma–a small airway disease: concepts and evidence. Pneumologie. 2009;63(Suppl 2):S96–101. doi: 10.1055/s-0029-1214715
   PubMedGoogle Scholar
• Weibel ER, Sapoval B, Filoche M. Design of peripheral airways for efficient gas exchange. Respir Physiol & Neurobiol. 2005;148(1–2):3–21. doi:10.1016/j.resp.2005.03.005
   PubMed Web of Science ®Google Scholar
• McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. Eur Clin Respir J. 2014;1(1):25898. doi: 10.3402/ecrj.v1.25898
   PubMedGoogle Scholar
• Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis. 1980;122(2):265–221. doi: 10.1164/arrd.1980.122.2.265
   PubMedGoogle Scholar
• Macklem PT, Proctor DF, Hogg JC. The stability of peripheral airways. Respiration Physiol. 1970;8(2):191–203. doi:10.1016/0034-5687(70)90015-0
   PubMedGoogle Scholar
• Higham A, Quinn AM, Cançado JED, et al. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res. 2019;20(1):49. doi:10.1186/s12931-019-1017-y
   PubMed Web of Science ®Google Scholar
• Florez-Sampedro L, Song S, Melgert BN. The diversity of myeloid immune cells shaping wound repair and fibrosis in the lung. Regeneration. 2018;5(1):3–25. doi:10.1002/reg2.97
   PubMedGoogle Scholar
• Dupin I, Thumerel M, Maurat E, et al. Fibrocyte accumulation in the airway walls of COPD patients. Eur Respir J. 2019;54(3):1802173. doi: 10.1183/13993003.02173-2018
   PubMed Web of Science ®Google Scholar
• Singh D, Long G, Cançado JED, et al. Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician. Curr Opin Pulm Med. 2020;26(2):162–168. doi:10.1097/MCP.0000000000000637
   PubMed Web of Science ®Google Scholar
• Olloquequi J, Ferrer J, Montes JF, et al. Differential lymphocyte infiltration in small airways and lung parenchyma in COPD patients. Respir Med. 2010;104(9):1310–1318. doi: 10.1016/j.rmed.2010.03.002
   PubMed Web of Science ®Google Scholar
• Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med. 2002;166(1):105–110. doi: 10.1164/rccm.2111084
   PubMed Web of Science ®Google Scholar
• Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J. 2001;17(5):946–953. doi: 10.1183/09031936.01.17509460
   PubMed Web of Science ®Google Scholar
• Gosman MME, Postma DS, Vonk JM, et al. Association of mast cells with lung function in chronic obstructive pulmonary disease. Respir Res. 2008;9(1):64. doi: 10.1186/1465-9921-9-64
   PubMed Web of Science ®Google Scholar
• Booth S, Hsieh A, Mostaco-Guidolin L, et al. A single-cell atlas of small airway disease in chronic obstructive pulmonary disease: a cross-sectional study. Am J Respir Crit Care Med. 2023;208(4):472–486. doi: 10.1164/rccm.202303-0534OC
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653. doi: 10.1056/NEJMoa032158
   PubMed Web of Science ®Google Scholar
• Leopold PL, O’Mahony MJ, Lian XJ, et al. Smoking is associated with shortened airway cilia. PLOS ONE. 2009;4(12):e8157. doi: 10.1371/journal.pone.0008157
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu FSF, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 2007;176(5):454–459. doi: 10.1164/rccm.200612-1772OC
   PubMed Web of Science ®Google Scholar
• Polosukhin VV, Richmond BW, Rui-Hong Du. Secretory IgA deficiency in individual small airways is associated with persistent inflammation and remodeling. Am J Respir Crit Care Med. 2017;195(8):1010–1021. doi: 10.1164/rccm.201604-0759OC
   PubMed Web of Science ®Google Scholar
• Utokaparch S, Sze MA, Gosselink JV, et al. Respiratory viral detection and small airway inflammation in lung tissue of patients with stable, mild COPD. J Chronic Obstr Pulm Disease. 2014;11(2):197–203. doi: 10.3109/15412555.2013.836166
   Web of Science ®Google Scholar
• Jalalvand F, Su Y-C, Mörgelin M, et al. Haemophilus influenzae protein F mediates binding to laminin and human pulmonary epithelial cells. J Infect Dis. 2013;207(5):803–813. doi: 10.1093/infdis/jis754
   PubMed Web of Science ®Google Scholar
• Abdillahi SM, Bober M, Nordin S, et al. Collagen VI is upregulated in COPD and serves both as an adhesive target and a bactericidal barrier for Moraxella catarrhalis. J Innate Immun. 2015;7(5):506–517. doi: 10.1159/000381213
   PubMed Web of Science ®Google Scholar
• Ramírez-Venegas A, Torres-Duque CA, Guzmán-Bouilloud NE, et al. Smalla airway disease in copd associated to biomass exposure. Rev Invest Clin. 2019;71(1):70–78. doi: 10.24875/RIC.18002652
   PubMedGoogle Scholar
• Rivera RM, Cosio MG, Ghezzo H, et al. Comparison of lung morphology in COPD secondary to cigarette and biomass smoke. Int J Tuberc Lung Dis. 2008;12(8):972–977.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Dhand R, Lavorini F, et al. Why we should target small airways disease in our management of chronic obstructive pulmonary disease. Mayo Clinic Proc. 2021;96(9):2448–2463. doi: 10.1016/j.mayocp.2021.03.016
   PubMed Web of Science ®Google Scholar
• Elbehairy AF, Parraga G, Webb KA, et al. Mild chronic obstructive pulmonary disease: why spirometry is not sufficient! Expert Rev Respir Med. 2017;11(7):549–563. doi:10.1080/17476348.2017.1334553
   PubMed Web of Science ®Google Scholar
• Chetta A, Pisi R, Aiello M, et al. Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1191–1197. doi: 10.2147/COPD.S82509
   PubMed Web of Science ®Google Scholar
• Saint-Pierre M, Ladha J, Berton DC, et al. Is the slow vital capacity clinically useful to uncover airflow limitation in subjects with preserved FEV1/FVC ratio? Chest. 2019;156(3):497–506. doi: 10.1016/j.chest.2019.02.001
   PubMed Web of Science ®Google Scholar
• McFadden ER, Linden DA. A reduction in maximum mid-expiratory flow rate. A spirographic manifestation of small airway disease. Am J Med. 1972;52(6):725–737. doi:10.1016/0002-9343(72)90078-2
   PubMed Web of Science ®Google Scholar
• Stockley JA, Ismail AM, Hughes SM, et al. Maximal mid-expiratory flow detects early lung disease in α1-antitrypsin deficiency. Eur Respir J. 2017;49(3):1602055. doi: 10.1183/13993003.02055-2016
   PubMed Web of Science ®Google Scholar
• Morris ZQ, Coz A, Starosta D. An isolated reduction of the FEV3/FVC ratio is an indicator of mild lung injury. Chest. 2013;144(4):1117–1123. doi:10.1378/chest.12-2816
   PubMed Web of Science ®Google Scholar
• Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70–e88. doi: 10.1164/rccm.201908-1590ST
   PubMed Web of Science ®Google Scholar
• Bonini M, Usmani OS. The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2015;9(6):281–293. doi:10.1177/1753465815588064
   PubMed Web of Science ®Google Scholar
• Dilektasli AG, Porszasz J, Casaburi R, et al. A novel spirometric measure identifies mild COPD unidentified by standard criteria. Chest. 2016;150(5):1080–1090. doi: 10.1016/j.chest.2016.06.047
   PubMed Web of Science ®Google Scholar
• Stringer WW, Porszasz J, Bhatt SP, et al. Physiologic insights from the COPD genetic epidemiology study. Chronic Obstr Pulm Dis. 2019;6(3):256–266. doi: 10.15326/jcopdf.6.3.2019.0128
   PubMed Web of Science ®Google Scholar
• Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11(1):79. doi:10.1186/1465-9921-11-79
   PubMedGoogle Scholar
• D’Ascanio M, Viccaro F, Calabrò N, et al. Assessing static lung hyperinflation by whole-body plethysmography, helium dilution, and impulse oscillometry system (IOS) in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:2583–2589. doi: 10.2147/COPD.S264261
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi: 10.1056/NEJMoa021322
   PubMed Web of Science ®Google Scholar
• Marin JM, Carrizo SJ, Gascon M, et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(6):1395–1399. doi:10.1164/ajrccm.163.6.2003172
   PubMed Web of Science ®Google Scholar
• Konstantinos Katsoulis K, Kostikas K, Kontakiotis T. Techniques for assessing small airways function: possible applications in asthma and COPD. Respir Med. 2016;119:e2–e9. doi:10.1016/j.rmed.2013.05.003
   PubMedGoogle Scholar
• Stockley JA, Cooper BG, Stockley RA, et al. Small airways disease: time for a revisit? Int J Chron Obstruct Pulmon Dis. 2017;12:2343–2353. doi:10.2147/COPD.S138540
   PubMed Web of Science ®Google Scholar
• Bickel S, Popler J, Lesnick B, et al. Impulse oscillometry: interpretation and practical applications. Chest. 2014;146(3):841–847. doi:10.1378/chest.13-1875
   PubMed Web of Science ®Google Scholar
• Wei X, Shi Z, Cui Y, et al. Impulse oscillometry system as an alternative diagnostic method for chronic obstructive pulmonary disease. Medicine (Baltimore). 2017;96(46):e8543. doi: 10.1097/MD.0000000000008543
   PubMed Web of Science ®Google Scholar
• Li L-Y, Yan T-S, Yang J, et al. Impulse oscillometry for detection of small airway dysfunction in subjects with chronic respiratory symptoms and preserved pulmonary function. Respir Res. 2021;22(1):68. doi: 10.1186/s12931-021-01662-7
   PubMed Web of Science ®Google Scholar
• Chiu H-Y, Hsiao Y-H, Su K-C, et al. Small airway dysfunction by impulse oscillometry in symptomatic patients with preserved pulmonary function. J Allergy Clin Immunol Pract. 2020;8(1):229–235.e223. doi: 10.1016/j.jaip.2019.06.035
   PubMed Web of Science ®Google Scholar
• Lu L, Peng J, Zhao N, et al. Discordant spirometry and impulse oscillometry assessments in the diagnosis of small airway dysfunction. Front Physiol. 2022;13:892448. doi: 10.3389/fphys.2022.892448
   PubMed Web of Science ®Google Scholar
• Chetta A, Facciolongo N, Franco C, et al. Small airways disease, and extra-fine formulations in asthma and chronic obstructive pulmonary disease: windows for new opportunities. Ther Clin Risk Manag. 2022;18:965–979. doi: 10.2147/TCRM.S369876
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Pecchiari M, et al. The relevance of targeting treatment to small airways in asthma and COPD. Respir Care. 2020;65(9):1392–1412. doi: 10.4187/respcare.07237
   PubMed Web of Science ®Google Scholar
• Milic-Emili J, Torchio R, D’Angelo E. Closing volume: a reappraisal (1967–2007). Eur J Appl Physiol. 2007;99(6):567–583. doi: 10.1007/s00421-006-0389-0
   PubMed Web of Science ®Google Scholar
• Boeck L, Gensmer A, Nyilas S, et al. Single-breath washout tests to assess small airway disease in COPD. Chest. 2016;150(5):1091–1100. doi: 10.1016/j.chest.2016.05.019
   PubMed Web of Science ®Google Scholar
• Stanojevic S, Bowerman C, Robinson P. Multiple breath washout: measuring early manifestations of lung pathology. Breathe. 2021;17(3):210016. doi:10.1183/20734735.0016-2021
   Web of Science ®Google Scholar
• Daynes E, Greening N, Owers-Bradley J, et al. The validity of shortened multiple-breath washout testing using sulfur hexafluoride in the assessment of patients with COPD. ERJ Open Res. 2021;7(3):00379–2020. doi: 10.1183/23120541.00379-2020
   PubMedGoogle Scholar
• Lynch DA. Imaging of small airways disease and chronic obstructive pulmonary disease. Clin Chest Med. 2008;29(1):165–179, vii.doi:10.1016/j.ccm.2007.11.008
   PubMed Web of Science ®Google Scholar
• Tanabe N, Shima H, Sato S, et al. Direct evaluation of peripheral airways using ultra-high-resolution CT in chronic obstructive pulmonary disease. Eur J Radiol. 2019;120:108687. doi: 10.1016/j.ejrad.2019.108687
   PubMed Web of Science ®Google Scholar
• Pike D, Kirby M, Guo F, et al. Ventilation heterogeneity in ex-smokers without airflow limitation. Acad Radiol. 2015;22(8):1068–1078. doi: 10.1016/j.acra.2015.04.006
   PubMed Web of Science ®Google Scholar
• Capaldi DPI, Zha N, Guo F, et al. Pulmonary imaging biomarkers of gas trapping and emphysema in COPD: (3)He MR imaging and CT parametric response maps. Radiology. 2016;279(2):597–608. doi: 10.1148/radiol.2015151484
   PubMed Web of Science ®Google Scholar
• Serajeddini H, Eddy RL, Licskai C, et al. FEV1 and MRI ventilation defect reversibility in asthma and COPD. Eur Respir J. 2020;55(3):1901947. doi: 10.1183/13993003.01947-2019
   PubMed Web of Science ®Google Scholar
• MacNeil JL, Capaldi DPI, Westcott AR, et al. Pulmonary imaging phenotypes of chronic obstructive pulmonary disease using multiparametric response maps. Radiology. 2020;295(1):227–236. doi: 10.1148/radiol.2020191735
   PubMed Web of Science ®Google Scholar
• Bajc M, Chen Y, Wang J, et al. Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease. Int J Chron Obstruct Pulmon Dis. 2017;12:1579–1587. doi: 10.2147/COPD.S131847
   PubMed Web of Science ®Google Scholar
• De Backer J, Vos W, Vinchurkar S, et al. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging. J Aerosol Med Pulm Drug Deliv. 2015;28(2):88–99. doi: 10.1089/jamp.2013.1064
   PubMed Web of Science ®Google Scholar
• Chukowry PS, Spittle DA, Turner AM. Small airways disease, biomarkers and COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2021;16:351–365. doi:10.2147/COPD.S280157
   PubMed Web of Science ®Google Scholar
• Young AL, Bragman FJS, Rangelov B, et al. Disease progression modeling in chronic obstructive pulmonary disease.Am j respir Crit Care Med. 2020;201(3):294–302.
   PubMed Web of Science ®Google Scholar
• Chen B, Liu Z, Lu J, et al. Deep learning parametric response mapping from inspiratory chest CT scans: a new approach for small airway disease screening. Respir Res. 2023;24(1):299. doi: 10.1186/s12931-023-02611-2
   PubMed Web of Science ®Google Scholar
• Wang JM, Bell AJ, Ram S, et al. Topologic parametric response mapping identifies tissue subtypes associated with emphysema progression. Acad Radiol. 2024;31(3):1148–1159. doi: 10.1016/j.acra.2023.08.003
   PubMed Web of Science ®Google Scholar
• Escamilla-Gil JM, Fernandez-Nieto M, Acevedo N, et al. Understanding the cellular sources of the fractional exhaled nitric oxide (FeNO) and its role as a biomarker of type 2 inflammation in asthma. Biomed Res Int. 2022;2022:1–9. doi: 10.1155/2022/5753524
   Web of Science ®Google Scholar
• Vincken S, Sylvia V, Daniel S, et al. The role of FeNO in stable COPD patients with eosinophilic airway inflammation. Respir Med. 2021;181:106377. doi: 10.1016/j.rmed.2021.106377
   PubMed Web of Science ®Google Scholar
• Alcázar-Navarrete B, Ruiz Rodríguez O, Conde Baena P, et al. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J. 2018;51(1):1701457. doi: 10.1183/13993003.01457-2017
   PubMed Web of Science ®Google Scholar
• Antus B, Barta I, Horvath I, et al. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology. 2010;15(3):472–477. doi: 10.1111/j.1440-1843.2010.01711.x
   PubMed Web of Science ®Google Scholar
• Lu Z, Huang W, Wang L, et al. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:2695–2705. doi:10.2147/COPD.S165780
   PubMed Web of Science ®Google Scholar
• Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J. 2005;25(6):986–991. doi: 10.1183/09031936.05.00132404
   PubMed Web of Science ®Google Scholar
• Fan X, Zhao N, Yu Z, et al. Clinical utility of central and peripheral airway nitric oxide in aging patients with stable and acute exacerbated chronic obstructive pulmonary disease. Int J Gen Med. 2021;14:571–580. doi: 10.2147/IJGM.S284688
   PubMed Web of Science ®Google Scholar
• Holz O, Waschki B, Roepcke S, et al. Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD. BMC Pulm Med. 2014;14(1):30. doi: 10.1186/1471-2466-14-30
   PubMedGoogle Scholar
• Chen M, Xu K, He Y, et al. CC16 as an inflammatory biomarker in induced sputum reflects chronic obstructive pulmonary disease (COPD) severity. Int J Chron Obstruct Pulmon Dis. 2023;18:705–717. doi: 10.2147/COPD.S400999
   PubMed Web of Science ®Google Scholar
• Robinson AB, Johnson KD, Bennion BG, et al. RAGE signaling by alveolar macrophages influences tobacco smoke-induced inflammation. Am J Physiol-Lung Cellular And Mol Physiol. 2012;302(11):L1192–L1199. doi:10.1152/ajplung.00099.2012
   PubMed Web of Science ®Google Scholar
• Ostridge K, Williams N, Kim V, et al. Relationship between pulmonary matrix metalloproteinases and quantitative CT markers of small airways disease and emphysema in COPD. Thorax. 2016;71(2):126–132. doi: 10.1136/thoraxjnl-2015-207428
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(1):6–14. doi: 10.1164/rccm.200510-1659PP
   PubMed Web of Science ®Google Scholar
• Pignatti P, Visca D, Cherubino F, et al. Do blood eosinophils strictly reflect airway inflammation in COPD? comparison with asthmatic patients. Respir Res. 2019;20(1):145. doi: 10.1186/s12931-019-1111-1
   PubMed Web of Science ®Google Scholar
• David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. doi:10.1136/thoraxjnl-2020-215167
   PubMed Web of Science ®Google Scholar
• Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993;92(4):537–548. doi: 10.1016/0091-6749(93)90078-T
   PubMed Web of Science ®Google Scholar
• Maetani T, Tanabe N, Sato A, et al. Association between blood eosinophil count and small airway eosinophils in smokers with and without COPD. ERJ Open Res. 2023;9(5). doi: 10.1183/23120541.00235-2023
   PubMedGoogle Scholar
• Abdo M, Pedersen F, Trinkmann F, et al. Association of airway eosinophilia with small airway dysfunction in patients with mild and at risk for COPD. Int J Chron Obstruct Pulmon Dis. 2022;17:1403–1408. doi: 10.2147/COPD.S366911
   PubMed Web of Science ®Google Scholar
• Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important? Eur Respir J. 2018;52(6):1801448. doi: 10.1183/13993003.01448-2018
   PubMed Web of Science ®Google Scholar
• Polverino F, Soriano JB. Small airways and early origins of COPD: pathobiological and epidemiological considerations. Eur Respir J. 2020;55(3):1902457. doi: 10.1183/13993003.02457-2019
   PubMed Web of Science ®Google Scholar
• Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med. 2012;44(2):146–156. doi:10.3109/07853890.2011.585656
   PubMed Web of Science ®Google Scholar
• Usmani OS. Treating the small airways. Respiration. 2012;84(6):441–453. doi:10.1159/000343629
   PubMed Web of Science ®Google Scholar
• Hillyer EV, Price DB, Chrystyn H, et al. Harmonizing the nomenclature for therapeutic aerosol particle size: a proposal. J Aerosol Med Pulm Drug Deliv. 2018;31(2):111–113. doi: 10.1089/jamp.2017.1396
   PubMed Web of Science ®Google Scholar
• Dhillon S, Keating GM. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs. 2006;66(11):1475–1483; discussion 1484. doi: 10.2165/00003495-200666110-00005
   PubMedGoogle Scholar
• Brown SM, Koarai A, Sturton RG, et al. A role for M(2) and M(3) muscarinic receptors in the contraction of rat and human small airways. Eur J Pharmacol. 2013;702(1–3):109–115. doi: 10.1016/j.ejphar.2013.01.054
   PubMed Web of Science ®Google Scholar
• Dahl R, Kaplan A. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? BMC Pulm Med. 2016;16(1):135. doi:10.1186/s12890-016-0291-4
   PubMed Web of Science ®Google Scholar
• Dahl R, Engel M, Dusser D, et al. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: a pooled safety analysis. Respir Med. 2016;118:102–111. doi: 10.1016/j.rmed.2016.07.001
   PubMed Web of Science ®Google Scholar
• Blair HA. Tiotropium/Olodaterol: a review in COPD. Drugs. 2019;79(9):997–1008. doi: 10.1007/s40265-019-01133-w
   PubMed Web of Science ®Google Scholar
• Pirina P, Foschino Barbaro MP, Paleari D, et al. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease. Respir Med. 2018;143:74–81. doi:10.1016/j.rmed.2018.08.013
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Nicolini G, Olivieri D, et al. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother. 2008;9(3):479–490. doi:10.1517/14656566.9.3.479
   PubMed Web of Science ®Google Scholar
• Papi A, Scichilone N, Benfante A, et al. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. Patient Relat Outcome Meas. 2014;5:153–162. doi: 10.2147/PROM.S55276
   PubMedGoogle Scholar
• Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–1162. doi: 10.1016/j.rmed.2014.05.013
   PubMed Web of Science ®Google Scholar
• Nicolini G, Crisafulli T, Nicolini C, et al. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis. 2011;6:503–509. doi: 10.2147/COPD.S23746
   PubMed Web of Science ®Google Scholar
• Sturton RG, Trifilieff A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel Once daily inhaled β 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther. 2008;324(1):270–275. doi:10.1124/jpet.107.129296
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2016;388(10048):963–973. doi: 10.1016/S0140-6736(16)31354-X
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2017;389(10082):1919–1929. doi: 10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. The Lancet. 2018;391(10125):1076–1084. doi: 10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Price DS, Postma D, Roche N, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:1163–1186. doi: 10.2147/COPD.S68289
   PubMed Web of Science ®Google Scholar
• Sonnappa S, Martin R, Israel E, et al. Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLOS ONE. 2017;12(6):e0178112. doi: 10.1371/journal.pone.0178112
   PubMed Web of Science ®Google Scholar
• Usmani OS, Scichilone N, Mignot B, et al. Airway deposition of extrafine inhaled triple therapy in patients with COPD: a model approach based on functional respiratory imaging computer simulations. Int J Chron Obstruct Pulmon Dis. 2020;15:2433–2440. doi: 10.2147/COPD.S269001
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rodriguez-Roisin R, Reisner C, et al. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:945–953. doi:10.2147/COPD.S154988
   PubMed Web of Science ®Google Scholar
• Doty A, Schroeder J, Vang K, et al. Correction to: drug delivery from an innovative LAMA/LABA Co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmScitech. 2018;19(6):2753. doi: 10.1208/s12249-017-0916-9
   PubMed Web of Science ®Google Scholar
• Grillet P-E, Le Souder C, Rohou J, et al. Glycopyrrolate and formoterol fumarate for the treatment of COPD. Expert Rev Respir Med. 2021;15(1):13–25. doi:10.1080/17476348.2020.1807946
   PubMed Web of Science ®Google Scholar
• Usmani O, Roche N, Wahab E, et al. A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respir Res. 2021;22(1):261. doi: 10.1186/s12931-021-01813-w
   PubMed Web of Science ®Google Scholar
• Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Lib. 2015. doi: 10.1002/14651858.CD001287.pub5
   Google Scholar
• Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106–118. doi: 10.1378/chest.12-2357
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205–214. doi: 10.1056/NEJMoa2303951
   PubMed Web of Science ®Google Scholar
• Castro M, Rabe KF, Corren J, et al. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res. 2020;6(1):00204–2019. doi: 10.1183/23120541.00204-2019
   PubMedGoogle Scholar
• Pelaia C, Lombardo N, Busceti MT, et al. Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis. J Asthma Allergy. 2021;14:1165–1172. doi: 10.2147/JAA.S328988
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Soler X, Wang X, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(2):178–184. doi: 10.1164/rccm.201511-2219OC
   PubMed Web of Science ®Google Scholar
• Pompe E, Moore CM, Mohamed Hoesein FAA, et al. Progression of emphysema and small airways disease in cigarette smokers. Chronic Obstr Pulm Dis. 2021;8(2):198–212. doi: 10.15326/jcopdf.2020.0140
   PubMed Web of Science ®Google Scholar
• Zhao N, Wu F, Peng J, et al. Preserved ratio impaired spirometry is associated with small airway dysfunction and reduced total lung capacity. Respir Res. 2022;23(1):298. doi: 10.1186/s12931-022-02216-1
   PubMed Web of Science ®Google Scholar
• Sharpe AL, Reibman J, Oppenheimer BW, et al. Role of small airway dysfunction in unexplained exertional dyspnoea. ERJ Open Res. 2023;9(3):00603–2022. doi: 10.1183/23120541.00603-2022
   PubMedGoogle Scholar